Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BMY – Bristol-Myers Squibb Company

Float Short %

1.52

Margin Of Safety %

32

Put/Call OI Ratio

0.78

EPS Next Q Diff

0.12

EPS Last/This Y

5.37

EPS This/Next Y

-0.49

Price

47.89

Target Price

52.35

Analyst Recom

2.67

Performance Q

1.89

Relative Volume

0.9

Beta

0.35

Ticker: BMY




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25BMY48.460.903.65624892
2025-07-28BMY47.510.981.41634739
2025-07-29BMY46.870.990.94642913
2025-07-30BMY46.010.981.31653927
2025-07-31BMY43.340.991.49680590
2025-08-01BMY44.220.960.42698087
2025-08-04BMY45.40.910.33689362
2025-08-05BMY45.830.900.61698229
2025-08-06BMY44.810.900.36700958
2025-08-07BMY45.370.880.77711379
2025-08-08BMY45.960.840.36732076
2025-08-11BMY45.920.841.07720671
2025-08-12BMY46.540.840.79722756
2025-08-13BMY47.850.840.23723524
2025-08-14BMY47.820.841.29735520
2025-08-15BMY48.390.830.35741707
2025-08-18BMY48.190.820.18606836
2025-08-19BMY48.380.790.38624663
2025-08-20BMY48.260.790.47640860
2025-08-21BMY48.410.810.12636878
2025-08-22BMY47.890.781.31651224
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25BMY48.43-44.07103.26.42
2025-07-28BMY47.42-45.46989.36.34
2025-07-29BMY46.86-45.47068.76.34
2025-07-30BMY45.98-45.47013.96.34
2025-07-31BMY43.31-46.86591.36.31
2025-08-01BMY44.23-46.87446.76.31
2025-08-04BMY45.40-5.87053.86.46
2025-08-05BMY45.85-5.86874.46.46
2025-08-06BMY44.81-6.26657.16.51
2025-08-07BMY45.36-6.27270.96.51
2025-08-08BMY45.95-6.27282.06.51
2025-08-11BMY45.93-6.27131.76.51
2025-08-12BMY46.54-6.27285.76.51
2025-08-13BMY47.85-6.27451.46.51
2025-08-14BMY47.82-6.27129.56.51
2025-08-15BMY48.47-6.27293.36.52
2025-08-18BMY48.18-6.27075.46.52
2025-08-19BMY48.34-6.27172.06.52
2025-08-20BMY48.26-6.27117.76.52
2025-08-21BMY48.41-6.27171.96.52
2025-08-22BMY47.89-6.27009.56.52
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25BMY0.492.951.89
2025-07-28BMY0.492.331.89
2025-07-29BMY0.492.331.89
2025-07-30BMY0.492.331.89
2025-07-31BMY0.492.331.89
2025-08-01BMY0.492.331.89
2025-08-04BMY0.492.981.89
2025-08-05BMY0.472.981.89
2025-08-06BMY0.472.981.89
2025-08-07BMY0.472.981.89
2025-08-08BMY0.472.981.89
2025-08-11BMY0.472.941.89
2025-08-12BMY0.472.941.52
2025-08-13BMY0.472.941.52
2025-08-14BMY0.472.941.52
2025-08-15BMY0.472.941.52
2025-08-18BMY0.471.451.52
2025-08-19BMY0.631.451.52
2025-08-20BMY0.481.451.52
2025-08-21BMY0.481.451.52
2025-08-22BMY0.311.451.52
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

1.46

Avg. EPS Est. Current Quarter

1.69

Avg. EPS Est. Next Quarter

1.58

Insider Transactions

0.31

Institutional Transactions

1.45

Beta

0.35

Average Sales Estimate Current Quarter

11754

Average Sales Estimate Next Quarter

12004

Fair Value

63.11

Quality Score

80

Growth Score

50

Sentiment Score

76

Actual DrawDown %

41.2

Max Drawdown 5-Year %

-47.7

Target Price

52.35

P/E

19.34

Forward P/E

7.96

PEG

0.27

P/S

2.04

P/B

5.59

P/Free Cash Flow

6.69

EPS

2.48

Average EPS Est. Cur. Y​

6.52

EPS Next Y. (Est.)

6.02

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

10.58

Relative Volume

0.9

Return on Equity vs Sector %

4.3

Return on Equity vs Industry %

-4.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

7009.5
Bristol-Myers Squibb Company
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 34100
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
stock quote shares BMY – Bristol-Myers Squibb Company Stock Price stock today
news today BMY – Bristol-Myers Squibb Company stock forecast ,stock prediction 2023 2024 2025
marketwatch BMY – Bristol-Myers Squibb Company yahoo finance google finance
stock history BMY – Bristol-Myers Squibb Company invest stock market
stock prices BMY premarket after hours
ticker BMY fair value insiders trading